COMPASS THERAPEUTICS INC (CMPX)

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) --  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

CMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024

CMPX stock results show that Compass Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or...

Which stocks are moving after the closing bell on Wednesday?

The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers,...

3 Penny Stocks With the Power to 10X Your $1K Investment

The 10X penny stocks discussed here are a much more reliable investment than many other alternatives investors are likely to encounter.

CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023

CMPX stock results show that Compass Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Compass Therapeutics (NASDAQ:CMPX) just reported results for the fourth quarter...

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update...

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

Compass Therapeutics provides updates regarding ongoing projects (NASDAQ:CMPX)

Compass Therapeutics, an oncology-focused biopharmaceutical company, provides updates on its operations, including timelines for clinical studies and its...

Compass Therapeutics Provides Corporate Update

We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in...

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Opened 29 clinical sites and continue to enroll patients in COMPANION-002, a U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in patients...

3 Healthcare Stocks To Make You The Millionaire Next Door: October Edition

These are the healthcare stocks to buy as they represent companies investing in research and development for growth and value creation.

Compass Therapeutics to Participate in Upcoming Investor Events

BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Continuing to enroll patients in a U.S. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC);...

Compass Therapeutics added to Russell indexes (NASDAQ:CMPX)

Compass Therapeutics (CMPX) said Thursday that it will be added to the Russell 2000 and Russell 3000 Indexes.The addition is part of the Russell indexes annual reconstitution,...

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

Top Buys by Top Brass: CHIEF EXECUTIVE OFFICER Schuetz's $355.3K Bet on CMPX

Compass Therapeutics to Participate in Upcoming Investor Events

BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

Compass Therapeutics GAAP EPS of -$0.06 (NASDAQ:CMPX)

Compass Therapeutics press release (CMPX): Q1 GAAP EPS of -$0.06.As of March 31, 2023, cash and marketable securities were $175 million as compared to $187 million as of December...

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC)....

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

(NASDAQ:CMPX)

Compass Therapeutics press release (CMPX): Q4 GAAP EPS of -$0.10. cash and marketable securities were $186.6 million